Type 2 Diabetes Mellitus Clinical Trial
— ACMYCOOfficial title:
A Double-Blind Randomised Controlled Trial Investigating the Acute Effects of Mycoprotein on Glycaemic Control and Appetite in South Asian and Caucasian Adults With Type 2 Diabetes Mellitus
NCT number | NCT03949582 |
Other study ID # | 18HH4870 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2019 |
Est. completion date | June 30, 2021 |
Diet is the cornerstone treatment to manage blood sugar in people with Type 2 Diabetes (T2D).
Fibres like guar gum and protein are macronutrients that have an effect in blood sugar
levels. Mycoprotein is a fungi-based food high in both dietary fibre and protein shown to
have a role in regulating blood sugar levels in healthy. However, little is known about the
effects of mycoprotein on blood sugar levels in people with T2D. We are interested in South
Asian because they have a different blood sugar response to the same food than a Caucasian.
The main aims of the study is to assess:
- The effect of mycoprotein in different formats (soup or mince) in blood sugar levels and
appetite in South Asian and Caucasian with Type 2 Diabetes.
- The effect of the combination of mycoprotein with guar gum in different formats (soup or
mince) in blood sugar levels and appetite in South Asian and Caucasian with T2D.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosed with Type 2 Diabetes Mellitus without insulin treatment. - South Asian (Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, India, Pakistan and Sri Lanka) or Caucasian Ancestry. - Age 18-70 - 5.5% = HbA1c = 9.0% - BMI = 35.0 - If anti-diabetic regime or lipid lowering drugs are used, they have to be stable and controlled for at least 2 months; regimes are expected to remain stable throughout the duration of the study or not being on anti-diabetic medication. - If on oral hypoglycaemic agent, participant should have the last dose at 8pm of the day before each study visit. - Willingness to comply with the study protocol, including: - Use of standard evening meal the day prior to the assessments - Refrain from alcohol consumption (24 h prior the visit) and extraneous physical exercise (72 h prior to and during the assessments). - Not changing physical activity routine or dietary habits for the duration of the study (except from the standard evening meal). Exclusion Criteria: - Not diagnosed with Type 2 Diabetes Mellitus - Mixed ancestors - Taking any of the following medications: - Insulin - Diabetic medication (except from Metformin or oral hypoglycaemic which are allowed). - Orlistat - Any gastrointestinal disease that interferes with bowel function and nutritional intake (i.e. Diabetes related constipation or diarrhoea secondary to neuropathy or chronic inflammatory bowel disease, gastrectomy, etc.) - Significant heart (New York Heart Association class IV), hepatic (transaminase levels greater than 3 times normal) or renal disease (requiring dialysis) - Cancer - Pancreatitis - Major infections (requiring antibiotics) within 3 weeks before study entry - Concomitant therapy with acarbose, meglitinides, insulin, systemic glucocorticoids or within 2 weeks prior to study entry - History of alcohol and/or drug abuse - Investigator's uncertainty about the willingness or ability of patient to comply with the protocol requirements - Participation in other nutrition trials within 3 months of study entry or drug trials within 5 months of study end - Current smokers - Allergic to test food or traces contained in the test food, breathing mould, penicillin, egg, soy - Asthmatics. - Any condition involving the imbalance of hormones - Hypothyroidism. - Weight change of = 5% in the preceding 3 months - Shift workers - Vegetarian - Medical implants that require batteries such as heart pace makers |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NIHR Imperial Clinical Research Facility | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood glucose | Fasting and Postprandial blood glucose | 180 minutes | |
Primary | Blood insulin | Fasting and Postprandial blood insulin | 180 minutes | |
Secondary | Subjective appetite feelings | Measured using Visual Analogue Scale from 0 to 100 milimetres, being 100 milimetres the higher score. Questions assessed are: "how hungry do you feel?" "how sick do you feel?" "how strong is your desire to eat?" "how much food do you think you could eat?" "how full do you feel?" "what is your level of satiety?" For questions 1 to 4 the desirable outcome considered as "good result" for the test food mycoprotein are values less than 30 milimetres, and for questions 5 and 6, values above 60 milimetres. |
180 minutes | |
Secondary | Ad libitum energy intake | Measured using a buffet meal composed of wihte pasta with tomato sauce and weighting the serving bowl before and after to measure consumed grams of food. | At timepoint 180 minutes | |
Secondary | Energy intake 72 hours post study visit | Energy intake of free-living subjects will be measured using self reported food diaries | For 3 days after study visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|